190 related articles for article (PubMed ID: 21142749)
1. Impact of bevacizumab chemotherapy on craniotomy wound healing.
Clark AJ; Butowski NA; Chang SM; Prados MD; Clarke J; Polley MY; Sughrue ME; McDermott MW; Parsa AT; Berger MS; Aghi MK
J Neurosurg; 2011 Jun; 114(6):1609-16. PubMed ID: 21142749
[TBL] [Abstract][Full Text] [Related]
2. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
Clark AJ; Lamborn KR; Butowski NA; Chang SM; Prados MD; Clarke JL; McDermott MW; Parsa AT; Berger MS; Aghi MK
Neurosurgery; 2012 Feb; 70(2):361-70. PubMed ID: 21841523
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
4. Wound healing complications in brain tumor patients on Bevacizumab.
Ladha H; Pawar T; Gilbert MR; Mandel J; O-Brien B; Conrad C; Fields M; Hanna T; Loch C; Armstrong TS
J Neurooncol; 2015 Sep; 124(3):501-6. PubMed ID: 26298437
[TBL] [Abstract][Full Text] [Related]
5. Management of a complex scalp defect.
Plast Reconstr Surg; 2008 Aug; 122(2):623-625. PubMed ID: 18626384
[No Abstract] [Full Text] [Related]
6. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H
J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771
[TBL] [Abstract][Full Text] [Related]
7. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience.
Nghiemphu PL; Liu W; Lee Y; Than T; Graham C; Lai A; Green RM; Pope WB; Liau LM; Mischel PS; Nelson SF; Elashoff R; Cloughesy TF
Neurology; 2009 Apr; 72(14):1217-22. PubMed ID: 19349600
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
12. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
13. The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma.
D'Amico RS; Cloney MB; Sonabend AM; Zacharia B; Nazarian MN; Iwamoto FM; Sisti MB; Bruce JN; McKhann GM
World Neurosurg; 2015 Oct; 84(4):913-9. PubMed ID: 26074434
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
15. Extremely late wound dehiscence following bevazicumab treatment in a long term survival glioblastoma patient.
Laviv Y; Rappaport ZH
Clin Neurol Neurosurg; 2014 Dec; 127():125-7. PubMed ID: 25459258
[No Abstract] [Full Text] [Related]
16. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
17. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
18. Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma: A long-term retrospective study in Taiwan.
Huang YK; Lieu AS
Medicine (Baltimore); 2020 Feb; 99(8):e19226. PubMed ID: 32080119
[TBL] [Abstract][Full Text] [Related]
19. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
20. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy.
Zawacki WJ; Walker TG; DeVasher E; Halpern EF; Waltman AC; Wicky ST; Ryan DP; Kalva SP
J Vasc Interv Radiol; 2009 May; 20(5):624-7; quiz 571. PubMed ID: 19328717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
